Signalling input from divergent pathways subverts B cell transformation-Reference-Cited by-同舟云学术

Signalling input from divergent pathways subverts B cell transformation

Published:2020-07-22 Issue:7818 Volume:583 Page:845-851
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Chan Lai N.,Murakami Mark A.,Robinson Mark E.^ORCID,Caeser Rebecca,Sadras Teresa,Lee Jaewoong,Cosgun Kadriye Nehir,Kume Kohei^ORCID,Khairnar Vishal,Xiao Gang,Ahmed Mohamed A.^ORCID,Aghania Eamon,Deb Gauri,Hurtz Christian,Shojaee Seyedmehdi,Hong Chao,Pölönen Petri,Nix Matthew A.^ORCID,Chen Zhengshan,Chen Chun Wei,Chen Jianjun^ORCID,Vogt Andreas^ORCID,Heinäniemi Merja^ORCID,Lohi Olli,Wiita Arun P.^ORCID,Izraeli Shai,Geng Huimin,Weinstock David M.,Müschen Markus^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41586-020-2513-4.pdf

Reference32 articles.

1. Fearon, E. R., Hamilton, S. R. & Vogelstein, B. Clonal analysis of human colorectal tumors. Science 238, 193–197 (1987).

2. Goetz, C. A., Harmon, I. R., O’Neil, J. J., Burchill, M. A. & Farrar, M. A. STAT5 activation underlies IL7 receptor-dependent B cell development. J. Immunol. 172, 4770–4778 (2004).

3. Malin, S. et al. Role of STAT5 in controlling cell survival and immunoglobulin gene recombination during pro-B cell development. Nat. Immunol. 11, 171–179 (2010).

4. Katerndahl, C. D. S. et al. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat. Immunol. 18, 694–704 (2017).

5. Shaw, A. C., Swat, W., Ferrini, R., Davidson, L. & Alt, F. W. Activated Ras signals developmental progression of recombinase-activating gene (RAG)-deficient pro-B lymphocytes. J. Exp. Med. 189, 123–129 (1999).

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lipopolymer/siRNA Nanoparticles Targeting the Signal Transducer and Activator of Transcription 5A Disrupts Proliferation of Acute Lymphoblastic Leukemia;ACS Pharmacology & Translational Science;2024-08-15

2. DUSP6 inhibition overcomes neuregulin/HER3-driven therapy tolerance in HER2+ breast cancer;EMBO Molecular Medicine;2024-06-17

3. Mutation and cell state compatibility is required and targetable in Ph+acute lymphoblastic leukemia minimal residual disease;2024-06-10

4. The case for therapeutic overactivation of oncogenic signaling as a potential cancer treatment strategy;Cancer Cell;2024-06

5. Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy;Cancer Discovery;2024-03-26